Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
38.10
+1.28 (3.48%)
Jan 21, 2025, 4:00 PM EST - Market closed
Protagonist Therapeutics Employees
Protagonist Therapeutics had 112 employees as of December 31, 2023. The number of employees increased by 7 or 6.67% compared to the previous year.
Employees
112
Change (1Y)
7
Growth (1Y)
6.67%
Revenue / Employee
$2,891,027
Profits / Employee
$1,525,438
Market Cap
2.27B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
PTGX News
- 8 days ago - Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck - Seeking Alpha
- 15 days ago - Protagonist Therapeutics Reports Granting of Inducement Awards - Accesswire
- 4 weeks ago - Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - Accesswire
- 2 months ago - Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 - Accesswire
- 2 months ago - Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate - Accesswire
- 2 months ago - Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Accesswire
- 2 months ago - Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting - Accesswire
- 4 months ago - Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - Benzinga